April 3, 2018 / 12:18 PM / 4 months ago

BRIEF-Sancilio Pharma Says Sickle Cell Treatment Receives EMA Orphan Drug Status

April 3 (Reuters) - Sancilio Pharmaceuticals Co Inc :

* COMPANY ANNOUNCES ALTEMIA™ RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE (SCD)

* ‍SPCI PLANS TO PRESENT DETAILED DATA FROM COMPLETED SCOT PHASE 2 STUDY IN PEER REVIEWED JOURNALS & SCIENTIFIC CONFERENCES​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below